MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
Achieved landmark milestone with positive results from Phase 2 MIRA trial in hidradenitis suppurativa (HS),…
Achieved landmark milestone with positive results from Phase 2 MIRA trial in hidradenitis suppurativa (HS),…
Achieved landmark milestone with positive results from Phase 2 MIRA trial in hidradenitis suppurativa (HS),…
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of…
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of…
Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer…
Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer…
Initial data from the Phase 1 clinical trial of IMVT-1402 on track for September 2023…
Initial data from the Phase 1 clinical trial of IMVT-1402 on track for September 2023…
Ms. Gina Chapman Ms. Gina Chapman BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) — Entrada Therapeutics,…
Ms. Gina Chapman Ms. Gina Chapman BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) — Entrada Therapeutics,…
Initiation cleared for 50 mg cohort in Phase 2 Friedreich’s ataxia (FA) dose exploration trial…
Initiation cleared for 50 mg cohort in Phase 2 Friedreich’s ataxia (FA) dose exploration trial…
Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Commenced enrollment…
Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Commenced enrollment…
Ninth patient dosed in ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation;…
Ninth patient dosed in ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation;…
Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year…
Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year…
– Received second IND application clearance for CABA-201 in myositis as well as Fast Track…
– Received second IND application clearance for CABA-201 in myositis as well as Fast Track…